In vivo binding of NF-κB to the IκBβ promoter is insufficient for transcriptional activation by Griffin, Bryan D. & Moynagh, Paul N.
Biochem. J. (2006) 400, 115–125 (Printed in Great Britain) doi:10.1042/BJ20060786 115
In vivo binding of NF-κB to the IκBβ promoter is insufficient
for transcriptional activation
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UCD School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland
Despite certain structural and biochemical similarities, differ-
ences exist in the function of the NF-κB (nuclear factor κB) inhibi-
tory proteins IκBα (inhibitory κBα) and IκBβ. The functional
disparity arises in part from variance at the level of gene regu-
lation, and in particular from the substantial induction of IκBα,
but not IκBβ, gene expression post-NF-κB activation. In the
present study, we probe the differential effects of IL (interleukin)-
1β on induction of IκBα and perform the first characterization
of the human IκBβ promoter. A consensus NF-κB-binding site,
capable of binding NF-κB both in vitro and in vivo, is found in
the IκBβ gene 5′ flanking region. However, the IκBβ promoter
was not substantially activated by pro-inflammatory cytokines,
such as IL-1β and tumour necrosis factor α, that are known to
cause strong activation of NF-κB. Furthermore, in contrast with
IκBα, NF-κB activation did not increase expression of endo-
genous IκBβ as assessed by analysis of mRNA and protein levels.
Unlike κB-responsive promoters, IκBβ promoter-bound p65 inef-
ficiently recruits RNA polymerase II, which stalls at the promoter.
We present evidence that this stalling is likely due to the ab-
sence of transcription factor IIH engagement, a prerequisite for
RNA polymerase II phosphorylation and transcriptional initi-
ation. Differences in the conformation of promoter-bound NF-κB
may underlie the variation in the ability to engage the basal tran-
scriptional apparatus at the IκBβ and κB-responsive promoters.
This accounts for the differential expression of IκB family mem-
bers in response to NF-κB activation and furthers our understand-
ing of the mechanisms involved in transcription factor activity
and IκBβ gene regulation.
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INTRODUCTION
The inducible expression of a wide range of immune and inflam-
matory response genes is controlled by the action of NF-κB
(nuclear factor κB) [1]. NF-κB is a dimeric factor, comprised
of members of the Rel family of proteins, some of which are tran-
scriptionally active – p65, c-Rel (the product of the cellular
homologue of the avian-recticuloendotheliosis-virus transform-
ing gene) and RelB, while others lack TADs (transcriptional activ-
ation domains) and are synthesized as longer inactive precursors –
p105 (p50) and p100 (p52) [2]. Rel proteins share a conserved
300-amino-acid N-terminal region known as the RHD (Rel homo-
logy domain) that contains regions responsible for dimerization,
nuclear localization and site-specific DNA binding. The RHD is
also responsible for mediating interactions with members of the
IκB (inhibitory κB) family of proteins [3]. IκBα and IκBβ,
the most extensively characterized members of this family, dis-
play numerous structural similarities. They contain a central an-
kyrin repeat domain responsible for association with NF-κB with
1:1 stoichiometry [4,5]. The interaction maintains NF-κB in an
inactive state in unstimulated cells. In addition, IκBα and IκBβ
contain specific N-terminal serine residues that are phosphoryl-
ated in response to NF-κB-inducing stimuli [6,7]. This tags the
IκB protein for polyubiquitination and proteasome-mediated de-
gradation, allowing NF-κB to enter the nucleus and bind to target
promoters.
IκBα and IκBβ respond differently to the various inducers of
NF-κB. Whereas IκBα is degraded by all stimuli known to activ-
ate NF-κB, IκBβ proteolysis only occurs in response to a subset,
those causing long-term activation of the transcription factor [8].
As the IκBα gene is positively regulated by NF-κB, its expression
is rapidly induced following initial NF-κB activation [9]. The
newly synthesized protein can enter the nucleus, remove NF-κB
from its target promoters and return it to the cytoplasm [10]. This
inhibitory feedback accounts for the transient nature of the NF-κB
response produced by certain stimuli. The importance of IκBα for
regulating NF-κB was highlighted by studies on IκBα−/− mice,
which display developmental defects postnatally, dying within
8 days. The haemopoietic tissue of these animals show increased
levels of nuclear NF-κB and mRNAs of some NF-κB-responsive
genes. Furthermore, in IκBα−/− embryonic fibroblasts, where
signal-dependent NF-κB-activation is retained due to inhibition
by IκBβ, nuclear NF-κB remains elevated in response to TNFα
(tumour necrosis factor α) treatment relative to wild-type cells
[11]. Interestingly, knock-in mice, in which the IκBα gene is
replaced by the IκBβ gene under the control of the IκBα promoter,
do not display postnatal developmental abnormalities and show
an inducible NF-κB activation similar to wild-type animals [12].
This indicates that IκBβ can functionally compensate for IκBα,
and suggests that it is the strong NF-κB-mediated up-regulation
of IκBα expression that accounts for the main difference in IκBα
and IκBβ activity. However, IκBβ is also likely to play unique
roles in temporal regulation of NF-κB in some cell systems. We
have previously shown that IL (interleukin)-1β causes sustained
activation of NF-κB in human astrocytes and that this coincides
with strong induction of IκBα but lack of resynthesis of IκBβ [13].
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In the present study, we further probe the mechanisms underlying
the differential induction of the two IκB forms by IL-1β in this
system.
In contrast with IκBα, IκBβ expression in mouse is not strongly
up-regulated by NF-κB, although it does contain a κB site in its
promoter. Studies on the murine IκBβ promoter demonstrated
that this κB site confers modest inducibility to NF-κB activation
[14]. Such findings, coupled with our previous demonstration of
the lack of resynthesis of IκBβ in response to IL-1β in human
astrocytes, prompted us to perform the first characterization of
the human IκBβ promoter and more significantly explore its
regulation by NF-κB. In the present study, we clone the human
IκBβ promoter and identify a putative κB site. We show that NF-
κB can bind to this site in vitro, and more importantly that p65
binds to the IκBβ promoter in vivo in an IL-1β-dependent fashion.
However, this binding is insufficient to promote up-regulation of
IκBβ expression, as shown by the failure of NF-κB-activating
stimuli to trigger substantial IκBβ promoter firing in transient
transfections or to induce expression of endogenous IκBβ at the
mRNA or protein level. We further show that this is due to the in-
ability of DNA-bound p65 to efficiently recruit RNA Pol II (poly-
merase II) to the IκBβ promoter and also to the promoter-
proximal stalling of RNA Pol II, with the resulting absence of
transcriptional activity. This stalling appears to be due to the
failure of p65 binding to augment recruitment of the general tran-
scription factor TFIIH (transcription factor IIH), required for
transcriptional initiation, to the IκBβ promoter, in contrast with its
engagement at the κB-responsive IL-8 promoter. Given the critical
role of IκB proteins in regulating NF-κB, and the importance of
gene regulation in dictating IκB activity, probing the mechanisms
underlying the differential expression of IκBα and IκBβ is of
clear importance. The present study advances our understanding
of those mechanisms, and offers an explanation for the failure of
NF-κB to cause an induction of IκBβ expression.
MATERIALS AND METHODS
Materials
The human astrocytoma cell line, 1321N1, and HEK (human
embryonic kidney)-293 cell line were obtained from the European
Collection of Animal Cell Cultures (Salisbury, U.K.). DMEM
(Dulbecco’s modified Eagle’s medium), FCS (foetal calf serum),
penicillin/streptomycin and trypsin were from Gibco BRL.
Human IL-1β and TNFα were purchased from R&D Systems
Europe. The double-stranded oligonucleotide containing the HIV-
LTR (long terminal repeat) κB site and T4 polynucleotide
kinase were supplied by Promega. [γ -32P]ATP was purchased
from Amersham International. PCR primers and oligonucleotides
containing other κB site sequences were obtained from MWG
Biotech. GeneJuice transfection reagent was from Novagen. Pri-
mers and probes for quantitative real-time PCR analysis of IκBβ
and 18 S rRNA were supplied by Applied Biosystems. Rabbit
polyclonal antibodies against IκBα (sc-203), IκBβ (sc-945), p50
(H-119), p65 (sc-372), c-Rel (sc-70X), RNA Pol II (sc-899)
and p89 (sc-293) were obtained from Santa Cruz Biotechnology.
Mouse monoclonal anti-β-actin antibody was from Sigma. Affi-
nity-purified rabbit polyclonal antiserum against IκBε was a gift
from Nancy Rice (NCI-Frederick Cancer Research and Develop-
ment Center, Frederick, MD, U.S.A.).
Cell culture
The human astrocytoma cell line, 1321N1, and HEK-293 cell
line were cultured in DMEM supplemented with 100 units/ml of
penicillin, 100 µg/ml streptomycin and 10% (v/v) FCS. Cells
were maintained at 37 ◦C in a humidified atmosphere of 5% CO2.
All cells were passaged using 1% (w/v) trypsin in PBS. Cytokine
stimulation was performed on cells in a serum-containing medium
at 37 ◦C for all experiments.
5′-RACE (rapid amplification of cDNA ends)
RNA was isolated from 1321N1 astrocytoma using TRI Reagent
(Sigma). RLM-5′-RACE (RNA ligase-mediated 5′-RACE) was
performed using the GeneRacer kit (Invitrogen) according to
the manufacturer’s instructions. Purified RACE products were
TOPO-cloned into pCR2.1-TOPO (Invitrogen) and sequenced to
identify the 5′-end of the transcripts.
EMSA (electrophoretic mobility-shift assay)
Double-stranded oligonucleotides containing the IκBβ, IκBα-
κB1 and IκBα-κB2 NF-κB-binding sites were created by anneal-
ing the oligonucleotides 5′-AGTTGAGGGGAATTTCCCAGGC-
3′, 5′-AGTTGAGGGAAATTCCCCAGGC-3′ and 5′-AGTTGA-
GGGGAAACCCCCAGGC-3′ to their respective complementary
strands (putative κB sites are underlined). Annealing was per-
formed by incubating 100 pmol of each strand in 10 mM Tris/
HCl (pH 7.9) containing 2 mM MgCl2, 50 mM NaCl and 20 mM
EDTA at 90 ◦C for 5 min. The incubation was cooled slowly
to 50 ◦C, maintained at 50 ◦C for 5 min and then allowed to cool to
room temperature (21 ◦C). Double-stranded oligonucleotides were
labelled with [γ -32P]ATP (10 mCi/mmol) by T4 polynucleotide
kinase [15]. In EMSA analysis, nuclear extracts (10 µg of pro-
tein, generated as described previously [16]) were incubated with
30000 d.p.m. of probe. Incubations were performed for 30 min at
room temperature in 10 mM Tris/HCl buffer (pH 7.5) containing
100 mM NaCl, 1 mM EDTA, 5 mM DTT (dithiothreitol), 4%
(w/v) glycerol, 4 µg of poly(dI-dC) · (dI-dC) and 1 mg/ml nu-
clease-free BSA. In the supershift analysis, polyclonal antibody
(1 µg) against the NF-κB subunits p50, p65 or c-Rel, or non-
immune IgG was added to the extracts and chilled for 30 min
on ice prior to incubation with labelled oligonucleotide. In com-
petition analysis, unlabelled oligonucleotide was added to the
extracts and incubated for 20 min at room temperature (21 ◦C)
in a total volume of 25 µl before probe addition. All incubations
were subjected to electrophoresis on 4% (w/v) non-denaturing
polyacrylamide gels, which were subsequently dried and auto-
radiographed.
Promoter-reporter constructs and cell transfections
The HIV-LTR κB-, β-κB- and α-κB1-luciferase constructs con-
sisted of five consecutive copies of the HIV-LTR, IκBβ or IκBα-
κB1 κB sites cloned into XhoI/HindIII sites in the pGL3-Basic
reporter plasmid (Promega). To generate ‘β-Prom’, a 1 kb frag-
ment of the IκBβ gene 5′ flanking region was amplified from
1321N1 genomic DNA by PCR using the GC-rich PCR system
(Roche). The primers used were 5′-CCGCTCGAGCGGGAT-
GTGGAACAAGTCCGTCTCTCTC-3′ and 5′-CCCAAGCTTG-
GGTAAGGTTCACTCACGTGTCCCCATC-3′ (restriction sites
and clamps underlined). This fragment was also cloned into
XhoI/HindIII sites in the pGL3-Basic firefly luciferase plasmid
(Promega). For transfections using these constructs, HEK-293
cells (2 × 105 cells/ml) were plated on to 24-well plates and
allowed to grow for 24 h. Cells were then transfected using
GeneJuice transfection reagent with constitutively expressed
Renilla luciferase reporter construct (phRL-TK) (50 ng) and with
promoter-firefly luciferase construct or empty pGL3-Basic vector
(390 ng). Cells were allowed to recover overnight before treatment
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with IL-1β or TNFα (10 ng/ml) for 6 h. Cells treated with reporter
lysis buffer (Promega) and extracts were assayed for firefly
and Renilla luciferase activity using the luciferase assay system
(Promega) and coelenterazine (Sigma; 1 µg/ml) respectively.
Quantitative real-time PCR analysis of IκBβ expression
1321N1 astrocytoma (2 × 105 cells/ml; 3 ml) were plated on to
6-well plates and grown for 48 h. Cells were treated with IL-1β
(10 ng/ml) for various time periods. Cells were washed with PBS,
and RNA was extracted using TRI Reagent (Sigma). After DNase
I digestion, cDNA was generated from normalized RNA using
Superscript II reverse transcriptase. Samples were assayed by
quantitative real-time PCR for levels of IκBβ cDNA using the
ABI Prism 7900HT thermal cycler. Reactions were performed
using pre-validated primers and probes (Applied Biosystems).
p65 overexpression and Western immunoblotting
HEK-293 cells (2 × 105 cells/ml; 3 ml) were plated on to 6-well
plates and allowed to grow for 24 h. Cells were transfected using
GeneJuice transfection reagent with a p65 expression vector [p65–
RFP (red fluorescent protein)] or with empty RFP vector (1 µg).
After 24 h, medium was removed and cells were washed with
ice-cold PBS. The cells were scraped into PBS (1 ml) and pel-
leted by centrifugation at 20000 g for 5 min at 4 ◦C. After dis-
carding the supernatant, cells were resuspended in sample buffer
[62.5 mM Tris/HCl, pH 6.8, 2% (w/v) SDS, 10% (w/v) glycerol,
50 mM DTT and 0.01% (w/v) Bromophenol Blue; 100 µl per
sample] and chilled on ice for 10 min. Resuspended cells were
then boiled for 5 min. Cell debris was pelleted by further centri-
fugation at 20000 g for 10 min. The supernatant containing the
cell extract was removed to fresh Eppendorf tubes. Extracts were
separated by SDS/PAGE using a 12% (w/v) resolving gel and
proteins were transferred electrophoretically to nitrocellulose.
Immunodetection of proteins was conducted as described pre-
viously [13]. Blots were blocked in TBS [Tris-buffered saline
(20 mM Tris/HCl, pH 7.5, and 0.15 M NaCl)] and 5% (w/v)
non-fat dried skimmed milk powder (Marvel). Incubations with
primary antibodies against p65, IκBα, IκBβ, β-actin (all 1 µg/ml)
or IκBε (1:2000 dilution) were for 2 h at room temperature.
Horseradish-peroxidase-conjugated sheep anti-rabbit IgG and
horseradish-peroxidase-conjugated goat anti-mouse IgG (Upstate
Biotechnology) were used at concentrations of 1 and 0.5 µg/ml
respectively. Immunoreactive bands were detected using the en-
hanced chemiluminescence detection system from Pierce accord-
ing to the manufacturer’s instructions.
ChIP (chromatin immunoprecipitation)
1321N1 astrocytoma cells were grown to confluence in 90 mm
dishes and stimulated with or without IL-1β (10 ng/ml) for 1 h.
ChIP assays were performed as described previously with some
modifications [17]. Following stimulation, cells were cross-linked
with 1% formaldehyde for 10 min at 37 ◦C. Isolated nuclei were
subjected to seven 10 s sonication pulses from a Sanyo/MES
Soniprep 150 at one-third of total power. Separate aliquots from
each chromatin preparation were incubated overnight at 4 ◦C with
2 µg of anti-p65/Pol II antibody, or for 24 h with 8 µg of anti-
p89 antibody, and with non-immune rabbit IgG antibody. An ali-
quot was also retained as an input sample to normalize PCR
reactions and analyse shearing efficiency. The chromatin used had
an average size of 750 bp. After reversion of cross-links by over-
night incubation at 65 ◦C, DNA was extracted using the QIAquick
purification kit (Qiagen) according to the manufacturer’s instruc-
tions.
Figure 1 Nucleotide sequence of the IκBβ gene 5′ flanking region
A number of TSSs for the IκBβ gene were identified by 5′-RACE and are denoted by boldface
upper-case letters. The most 5′ site identified is designated +1. The translation start codon is
in boldface and is underlined. A putative κB site is located 5′ of the transcription window.
Standard PCR was performed using 1 µl (∼3% of total) tem-
plate DNA, 500 nM primers and 0.2 unit of Taq DNA polymerase
(Invitrogen) per 50 µl reaction. Quantitative real-time PCR re-
actions were performed in duplicate with 2 µl of template DNA,
50 nM primers and the SYBR Green Jumpstart Taq Readymix
(Sigma) in a total volume of 20 µl, using the Mx3000P QPCR
System (Stratagene). Dissociation curve analysis and gel electro-
phoresis of the final products confirmed that only the expected
specific amplicon of correct size was generated for each target
promoter. Real-time PCR data analysis was performed as des-
cribed previously [18]. Results for each treatment are expressed
as fold differences between DNA enrichment in the p65/Pol
II/p89-ChIP sample relative to IgG-ChIP sample. The sequences
of primers used are as follows: IκBα promoter 5′-GAAAGGA-
CCGGCAGGTTGGCAAAC-3′ and 5′-GGGTCAGGCTCGGG-
GAATTTC-3′, IκBα gene 5′-GTAGGATCAGCCCTCATTTT-
GTTGC-3′ and 5′-CTGTTACATGTCACAGGATACCACTG-
3′, IκBβ promoter 5′-GGAACGGCTAGAGAGTTGTAGTCC-3′
and 5′-CTTTGCCGGGAGTTCTGGAGCTTC-3′, IκBβ gene
5′-GATTCATTGCACGATGTCCAGTGTCTTC-3′ and 5′-CTA-
CTGTATGCTAGGCCTTGTGACCAC-3′, IL-8 promoter 5′-GG-
AAGTGTGATGACTCAGGTTTGC-3′ and 5′-GATGGTTCCT-
TCCGGTGGTTTCTTC-3′, IL-8 gene 5′-CCAAGGGCCAAG-
AGAATATCCGAAC-3′ and 5′-CTTCCACATGTCCTCACA-
ACATCAC-3′, IL-2 promoter 5′-CTTGCTCTTGTCCACCA-
CAATATGC-3′ and 5′-CAAAGACTGACTGAATGGATGTAG-
GTG-3′, GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
promoter 5′-CTACTAGCGGTTTTACGGGCG-3′ and 5′-TC-
GAACAGGAGGAGCAGAGAGCGA-3′.
RESULTS
Identification of TSS (transcription start site) of the IκBβ gene
In order to study regulation of IκBβ transcription in human cells,
we decided to characterize its promoter. However, it was initially
necessary to identify the TSS of the IκBβ gene. We employed
RLM-5′-RACE to identify the site. This approach identified nine
independent TSSs upstream of the translation start codon of the
IκBβ gene (Figure 1). 5′-RACE is a highly sensitive technique,
and the ligation of an RNA oligonucleotide to the 5′-end of
decapped RNA, and subsequent use of a primer specific for this
5′ oligonucleotide in conjunction with a gene-specific primer,
ensures the amplification of only full-length transcripts. A range
of TSSs, or ‘transcription window’, is not unusual in TATA-less,
GC-rich promoters. However, the detection of numerous sites is
in contrast with the murine IκBβ promoter, where a single major
TSS was detected in an S1 nuclease protection assay [19].
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The murine IκBβ gene 5′ flanking region contains an NF-κB-
binding site (κB site) 35 nucleotides upstream of the first TSS.
Analysis of the equivalent human region and alignment with the
murine promoter confirmed the presence of a consensus κB site
in the human IκBβ gene 5′ flanking region (Figure 1). Between
species there is variance at a single position – a change of C → T,
from mouse to human, at the third nucleotide from the 3′-end of
the decameric sequence. An interspecies comparison of 11 func-
tional κB sites has previously shown total conservation despite a
divergence in the sequence of surrounding regions, indicating the
importance of the cis-element sequence in conferring responsive-
ness to the appropriate trans-acting factor [20]. Nevertheless,
given that the human IκBβ promoter κB site retained the con-
sensus sequence (5′-GGGRNNYYCC-3′), and that this site had
been identified as a sequence capable of interacting with p65 and
c-Rel in early studies on optimal NF-κB-binding sites [21], we
decided to examine the functional relevance of this site and probed
its ability to interact with activated NF-κB in an in vitro assay.
NF-κB binds to the IκBβ promoter κB site in an IL-1β-dependent
manner in vitro
The binding of NF-κB to the IκBβ promoter κB site was initially
characterized using an in vitro assay. A range of oligonucleotides
containing single κB sites were radiolabelled for use in EMSA
analysis. Two of these oligonucleotides contained known, func-
tional κB sites from the IκBα promoter-designated α-κB1 and α-
κB2 [22]. A third included the κB site from the IκBβ promoter –
β-κB. Since we were especially interested in examining the dif-
ferential effects of IL-1β on IκBα and IκBβ expression in human
astrocytes, 1321N1 astrocytoma were used as an accepted model
of the astrocytic cell system in which IL-1β is known to cause
strong and sustained activation of NF-κB. Thus the probes were
individually incubated with nuclear extracts from 1321N1 cells
treated with or without IL-1β for 30 min. All three radiolabelled
probes were found to bind activated NF-κB (Figure 2A). Given
the ability of the β-κB site to bind NF-κB in vitro, additional
EMSA analysis was conducted to compare the NF-κB binding
to this site with that to the α-κB1 site. In a competition EMSA,
effective competition of NF-κB binding with radiolabelled β-κB
probe was achieved by pre-incubating nuclear extracts from cells
stimulated with IL-1β for 30 min with increasing concentrations
of unlabelled α-κB1 oligonucleotide (Figure 2B). Similarly,
unlabelled β-κB oligonucleotide competed the binding of NF-κB
to a radiolabelled α-κB1 probe. This indicates that the same form
of NF-κB can bind to the β-κB site and the α-κB1 site in vitro.
In addition, activated NF-κB appears to display similar affinity
for both κB sites, as a similar concentration of one unlabelled
oligonucleotide was required to eliminate binding to the other
radiolabelled probe.
To further characterize NF-κB binding to the β-κB site, nuclear
extracts from IL-1β-treated cells were pre-incubated with antisera
against the Rel proteins p50, p65 and c-Rel prior to addition
of radiolabelled β-κB probe and subsequent electrophoresis. As
shown above, IL-1β induces the activation of NF-κB, observed
here as two major complexes of similar electrophoretic mobility
(Figure 2C, lane 2). These IL-1β-induced complexes were un-
affected by pre-incubation with the non-immune IgG isotype
control (lane 6). Complexes I and II were supershifted by pre-
incubation with anti-p65 antiserum, with complex I disappearing
and complex II substantially reduced in intensity (lane 4). Pre-
incubation with anti-c-Rel antiserum also caused the appearance
of a faint supershifted complex, although this was not accomp-
anied by a significant decrease in the level of any IL-1β-induced
NF-κB–DNA complex (lane 5). This indicates that p65 was
contained in both of the IL-1β-induced NF-κB complexes that
bound to the β-κB site, while a complex containing c-Rel most
likely constitutes a fraction of either complex I or II. No supershift
was observed upon pre-incubation with anti-p50 antibody (lane 3).
The ability of both the anti-p50 and anti-c-Rel antibodies to cause
a supershift of NF-κB–DNA complexes was confirmed using a
radiolabelled probe containing the HIV-LTR κB site and nuclear
extracts from 1321N1 astrocytoma stimulated in the presence and
absence of IL-1β (Figures 2D and 2E).
Interestingly, an identical profile of supershifted complexes was
observed when EMSAs were performed with radiolabelled α-
κB1 following pre-incubation with anti-p65 or anti-c-Rel antisera
(Figure 2C, lanes 7–12). It therefore appears that despite the
difference in κB site sequence, the α-κB1 and β-κB sites bind
the same range of NF-κB dimers in vitro. The Rel subunits p65
and c-Rel harbour substantial transactivation potential, arising
from the presence of C-terminal TADs [23,24]. This suggests
that transcriptionally active complexes of NF-κB bind similarly
to the κB site of the IκBα and IκBβ promoters and that any
differences in IL-1β-induced expression of IκBα and IκBβ are
not due to the differential binding of NF-κB to the two promoters.
However, while the EMSA procedure offers information on the
ability of NF-κB to bind to oligonucleotides in vitro, transcription
factor interaction with cis-elements in the intact cell depends on
chromatin structure and promoter accessibility. Therefore we next
investigated whether NF-κB could bind to the IκBα and IκBβ
promoters in vivo.
p65 binds to the IκBβ promoter in vivo
ChIP studies were employed to examine whether IL-1β-mediated
NF-κB activation in human astrocytes led to the association of p65
with the IκBβ promoter in vivo. As NF-κB is known to mediate
the induction of IκBα following activation [9], binding to the
IκBα promoter was used as a positive control for this assay.
1321N1 astrocytoma were stimulated with or without IL-1β for
1 h prior to immunoprecipitation of nuclear lysates with anti-
p65 antisera. Intriguingly, analysis of immunoprecipitated DNA
by PCR indicated that p65 was present at both the IκBα and
IκBβ promoters 1 h post-IL-1β stimulation (Figure 3A). This was
corroborated by real-time PCR analysis of immunoprecipitated
DNA, where statistically significant levels of p65 binding to both
promoters was recorded in response to IL-1β (Figure 3B). The
specificity of IκBα and IκBβ promoter enrichment was confirmed
by the absence of GAPDH promoter in p65 immunoprecipitates.
In addition, p65 binding was not detected at the IL-2 promoter
by standard or real-time PCR of immunoprecipitated DNA. The
IL-2 gene is regulated by NF-κB, but is only expressed in T-cells.
Therefore the appearance of p65 at a promoter in response to
IL-1β is not a general phenomenon at all promoters containing
κB sites, but rather is specific to a subset, including the IκBβ
promoter. As IL-1β stimulation induced the binding of NF-κB
to the κB site of the IκBβ promoter in vitro, and resulted in p65
engagement of the IκBβ promoter in vivo, we next assessed the
ability of the human IκBβ κB site to confer inducibility on IL-1β
in functional assays.
The β-κB site confers low inducibility on IL-1β in transient
transfection assays
Promoter–reporter constructs containing five consecutive β-κB
or α-κB1 sites upstream of a luciferase reporter gene (β-κB–luci-
ferase and α-κB1–luciferase) were generated as described in the
Materials and methods section. HEK-293 cells transfected with
one of these constructs or empty pGL3-Basic vector were treated
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Figure 2 NF-κB binds to the κB site of the IκBβ promoter in vitro
1321N1 astrocytoma were treated with or without IL-1β (10 ng/ml) for 30 min before examining NF-κB DNA-binding activity by EMSA. (A) Nuclear extracts (10 µg of protein) were incubated
with radiolabelled oligonucleotides containing the IκBβ , IκBα-κB1 and IκBα-κB2 sites. (B) Nuclear extracts (10 µg of protein) were incubated with increasing amounts of unlabelled IκBα-κB1
oligonucleotide (0.07–1.75 pmol) or with an excess of unlabelled IκBβ-κB oligonucleotide (1.75 pmol) before addition of radiolabelled IκBβ-κB probe. Also, nuclear extracts were incubated with
increasing amounts of unlabelled IκBβ-κB oligonucleotide (0.07–1.75 pmol) or with an excess of unlabelled IκBα-κB1 oligonucleotide (1.75 pmol) before adding radiolabelled IκBα-κB1 probe.
(C) Nuclear extracts were pre-incubated with anti-p50, anti-p65, anti-c-Rel or non-immune (IgG) antibody. *Denotes an unidentified binding complex. (D, E) Nuclear extracts were pre-incubated with
non-immune (IgG) and anti-p50 (D) or anti-c-Rel (E) antibody before addition of radiolabelled probe containing the HIV-LTR κB site. The arrows indicate the mobility of supershifted complexes.
with or without IL-1β for 6 h before assessing reporter gene
activity. IL-1β stimulation caused a 10-fold induction of α-κB1–
luciferase expression. In contrast, only 2-fold induction of β-
κB–luciferase expression was observed upon IL-1β treatment
(Figure 4A). Together with the EMSA analysis, these data suggest
that while both the β-κB and α-κB1 sites bind identical forms
of NF-κB, stronger transactivation is seen from α-κB1-bound
NF-κB. The reason for the high basal level of β-κB–luciferase
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Figure 3 IL-1β induces p65 binding to the IκBβ gene promoter in vivo
1321N1 astrocytoma were treated with or without IL-1β (10 ng/ml) for 1 h. Nuclear lysates were generated and immunoprecipitated with anti-p65 or control IgG antibodies. Immunoprecipitated DNA
was analysed for IκBα, IκBβ , IL-2 and GAPDH promoters by PCR and gel electrophoresis (A) and IκBα, IκBβ and IL-2 promoters by quantitative real-time PCR (B). Data from real-time PCR are
expressed as fold differences between DNA enrichment in the anti-p65 ChIP sample relative to IgG ChIP sample and are displayed as means +− S.E.M. for three to five independent experiments.
*P < 0.05, **P < 0.01 versus unstimulated control (unpaired t test).
Figure 4 NF-κB causes strong activation of the IκBα promoter but weak activation of the IκBβ promoter in 1321N1 cells
(A) HEK-293 cells were co-transfected with α-κB1–luciferase, β-κB–luciferase or empty pGL3-Basic vector (EV), as well as phRL-TK (constitutively expressed Renilla luciferase). After overnight
recovery, cells were stimulated in the presence or absence of IL-1β (10 ng/ml) for 6 h. (B) HEK-293 cells were co-transfected with β-Prom, HIV-LTR κB-luc or empty pGL3-Basic vector (EV), and
phRL-TK. After overnight recovery, cells were stimulated in the presence or absence of IL-1β or TNFα (10 ng/ml) for 6 h. Cell lysates were assayed for firefly and Renilla luciferase. Data are presented
relative to untreated cells transfected with empty vector. Results represent means +− S.E.M. for three independent experiments.
activity relative to α-κB1–luciferase is currently unknown. How-
ever, EMSA analysis detected an unidentified complex binding to
the β-κB, but not α-κB1, probe, which was unaffected by IL-1β
treatment or pre-incubation with any anti-Rel subunit antisera
(Figure 2C, denoted by ‘*’). While sequence analysis did not
reveal the presence of any known cis-elements within the β-κB
site that were absent from the α-κB1 site, it is possible that this
complex represents a factor involved in stimulating basal levels
of reporter gene activity.
In order to determine whether the modest IL-1β-mediated in-
ducibility seen with the β-κB-luciferase construct was retained
within the context of the intact promoter, we next cloned the
human IκBβ 5′-flanking region. The IκBβ gene had previously
been assigned to chromosome band 19q13 by fluorescence in situ
hybridization [25]. A search of the NCBI database using the IκBβ
cDNA sequence identified a contig (CTC-360G5) containing the
IκBβ gene. An approx. 1 kb fragment of the 5′-flanking region
was amplified by PCR and cloned into the pGL3-Basic vector
upstream of the luciferase gene as described in the Materials
and methods section. HEK-293 cells transfected with the IκBβ-
promoter-reporter (β-Prom) or empty pGL3-Basic vector were
stimulated in the presence or absence of IL-1β or TNFα. β-Prom
displayed a high level of basal activity, approx. 20-fold over empty
vector (Figure 4B). Treatment with IL-1β and TNFα, another
pro-inflammatory cytokine known to activate NF-κB, caused a
1.3- and 1.5-fold induction of β-Prom activity respectively. In
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Figure 5 NF-κB causes strong induction of endogenous IκBα but fails to
up-regulate endogenous IκBβ gene expression in HEK-293 cells
HEK-293 cells were transfected with a plasmid expressing a p65–RFP fusion protein or empty
RFP vector. Cell lysates were generated after 24 h and subjected to SDS/PAGE and Western
immunoblotting to measure levels of p65, IκBα, IκBβ , IκBε and β-actin. These results are
representative of three independent experiments.
order to verify the responsiveness of HEK-293 cells to these cyto-
kines, cells were transfected with a promoter-reporter construct
containing a luciferase gene immediately downstream of five
tandemly repeated κB sites from the HIV LTR (HIV-LTR κB-
luc). IL-1β and TNF induced a 9- and 13-fold induction of reporter
gene activity respectively.
Thus transient transfections using β-κB–luciferase and the
IκBβ-promoter-reporter indicated that NF-κB activation does not
lead to substantial transactivation at the IκBβ promoter. As these
constructs constitute artificial extrachromosomal templates, we
also examined the effect of NF-κB activity on endogenous IκBβ
expression at the level of both mRNA and protein.
Activation of NF-κB does not induce endogenous
IκBβ gene expression
To examine whether IκBβ gene expression was induced by NF-κB
at the transcriptional level, 1321N1 astrocytoma were treated with
or without IL-1β, a strong activator of NF-κB, for various time
periods. mRNA levels were then quantified by real-time PCR. No
significant up-regulation of IκBβ mRNA was recorded following
IL-1β stimulation for 3, 8 or 24 h (results not shown). This
confirms our earlier Northern-blot analysis of IκBβ transcript
levels in response to activators of NF-κB [8,13]. As a positive
control, IL-8 mRNA levels were also monitored by quantitative
real-time PCR, with a robust up-regulation of mRNA expression
observed in response to IL-1β (results not shown). The effect of
NF-κB activation on IκBβ protein levels was also assessed. p65
was overexpressed in HEK-293 cells, before monitoring levels of
IκBα, IκBβ and another IκB family member, IκBε, by Western
immunoblotting (Figure 5). The expression of IκBα and IκBε is
known to be up-regulated by NF-κB [13], and this was reflected by
increased levels of these proteins detected in cells expressing the
p65–RFP fusion protein. However, levels of IκBβ were equivalent
in cells transfected with and without the p65 expression vector.
Together, these data demonstrate that expression of endogenous
IκBβ is not increased by activation of NF-κB, despite the binding
of p65 to the IκBβ promoter in an IL-1β-dependent manner.
As shown above, p65 was found to be present at the IκBβ pro-
moter following 1 h stimulation with IL-1β. The IκBβ mRNA
3′-UTR (untranslated region) does not contain an AU-rich se-
quence. This indicates that the transcript is not subject to rapid
turnover and, were mRNA levels to be up-regulated, this would
most likely be detectable at 3 h. In addition, previous Northern
blots performed by this group have demonstrated the absence of
an IκBβ mRNA induction after 1 h IL-1β treatment [13]. The
question thus remained as to how binding of p65 at the IκBβ
promoter failed to lead to transcriptional activation. To address
this issue, we returned to ChIP analysis of the IκBβ promoter,
monitoring the recruitment of a critical component of the
transcriptional machinery, RNA Pol II.
p65 binding to the IκBβ promoter results in relatively inefficient
recruitment and stalling of RNA Pol II at the promoter
Transcriptional activators operate by binding to a gene promoter
and increasing the rate of transcriptional initiation. Following
site-specific DNA binding, p65 can recruit components of the
basal transcription apparatus either directly or indirectly, via
co-activators such as CBP [CREB (cAMP-response-element-
binding)-binding protein]/p300 [26–28]. Following initiation of
transcription, RNA Pol II moves along the gene in the elongation
phase. The presence or absence of RNA Pol II at a gene promoter,
and within the gene at sites distant from the TSS, provides a
picture of the transcriptional status of that gene. We chose three
target genes in which to monitor RNA Pol II activity, IκBα, IκBβ
and IL-8. p65 binds to the promoters of all three targets in an
IL-1β-dependent manner (Figure 3 and [16]).
As for p65-ChIP analysis, 1321N1 astrocytoma cells were
treated with or without IL-1β for 1 h. Following anti-Pol II im-
munoprecipitation of nuclear lysates, immunoprecipitated DNA
was analysed for the presence of target sequences by standard and
quantitative real-time PCR (Figure 6). For each gene, amplific-
ation of two target sequences was performed. The first was located
in the promoter, just upstream of the TSS. The second was at least
2000 bp downstream from the TSS. As the average size of soni-
cated chromatin was 750 bp, this second target was considered to
be sufficiently far from the TSS to avoid false positive results,
otherwise attainable by the immunoprecipitation of RNA
Pol II stalled at the upstream promoter. While absent from
the IL-8 promoter in the basal state, RNA Pol II binding
occurred following IL-1β stimulation. Furthermore, the enzyme
was detected downstream in the IL-8 gene, in response to IL-1β,
demonstrating the effectiveness of Pol II-ChIP as a method to
study IL-1β-induced changes in transcriptional activity at target
genes. Some RNA Pol II was present at the IκBα promoter
in the basal state, but an increase in binding was observed in
response to IL-1β, and this increase was deemed statistically sig-
nificant by analysis of quantitative real-time PCR results. In
addition, examination of a downstream region of the IκBα gene
showed that active transcription is in progress 1 h post-IL-1β
stimulation.
As shown earlier, IL-1β induces binding of p65 to the IκBβ
promoter in vivo, but this is not accompanied by an up-regulation
of gene expression. Pol II ChIP showed that RNA Pol II is
found at the IκBβ promoter in unstimulated cells. IL-1β treat-
ment tended to cause some further recruitment of the enzyme.
While quantitative real-time PCR indicated that the increase was
approx. 2-fold, it was not found to be statistically significant at
P < 0.05. No RNA Pol II was detected downstream within the
IκBβ gene sequence in the presence or absence of IL-1β. This
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Figure 6 Stimulation of 1321N1 cells with IL-1β results in relatively inefficient recruitment and stalling of RNA Pol II at the IκBβ promoter
1321N1 astrocytoma were stimulated in the presence or absence of IL-1β (10 ng/ml) for 1 h. Nuclear lysates were generated and immunoprecipitated with anti-Pol II or control IgG antibodies.
Immunoprecipitated DNA was analysed for IL-8, IκBα and IκBβ promoter and gene sequences by PCR and gel electrophoresis (A) and by quantitative real-time PCR analysis (B). Data from real-time
PCR are expressed as fold differences between DNA enrichment in the anti-Pol II ChIP sample relative to IgG ChIP sample and are displayed as means +− S.E.M. for three independent experiments.
*P < 0.05, **P < 0.01 versus unstimulated control (unpaired t -test).
indicates that while IL-1β induces the binding of NF-κB to the
IκBβ promoter, p65 is relatively inefficient at recruiting RNA
Pol II to the TSS, and furthermore, the recruited polymerase stalls
at the promoter.
p65 binding to the IκBβ promoter is not followed
by TFIIH recruitment
In the stepwise assembly model of transcriptional initiation, pre-
initiation complex formation is completed by the loading of TFIIH
[29]. This multi-subunit general transcription factor possesses a
DNA helicase and a kinase activity, the latter of which phos-
phorylates the evolutionarily conserved heptapeptide repeat in
the CTD (C-terminal domain) of RNA Pol II. This modific-
ation appears necessary for transcriptional initiation, possibly by
inducing a conformational change that allows the polymerase
to disengage from the pre-initiation complex [30]. In order to
probe the mechanism underlying the failure of IκBβ promoter-
bound RNA Pol II to initiate transcription, ChIP assays were
performed to assess the genomic location of p89, the largest TFIIH
subunit, following IL-1β treatment of 1321N1 astrocytoma. Stan-
dard and real-time PCRs of p89-immunoprecipitated DNA
demonstrated that IL-1β caused loading of p89 on the IL-8 pro-
moter, with real-time PCR recording a 9-fold induction of binding.
However, no binding was detectable at the IκBβ promoter (Fig-
ures 7A and 7B). This strongly suggests that the absence of IκBβ
promoter firing in response to NF-κB activation stems from the
failure of DNA-bound p65 to efficiently recruit RNA Pol II and
to directly or indirectly engage TFIIH, with a resulting lack of
RNA Pol II CTD phosphorylation and promoter clearance. This
is a highly credible mechanism underlying the non-inducibility of
the IκBβ gene by NF-κB, and thus IL-1β, in human astrocytes.
DISCUSSION
The activity of transcription factors must be tightly marshalled
to avoid inappropriate gene expression. IκB proteins are charged
with regulating NF-κB activity. A notable disparity in the regu-
lation of IκBα and IκBβ expression is the strong induction of
the former, but not the latter, in response to NF-κB activation. As
functional compensation by IκBβ did not occur in IκBα−/− mice,
it has been proposed that it is the up-regulation of IκBα, but not
IκBβ, following activation of NF-κB that underlies the difference
in activity of the two IκBs. In a study of the murine IκBβ promoter,
Budde et al. [14] identified a κB site upstream of the TSS and
demonstrated that NF-κB could bind to the site and cause modest
transcriptional activation. The human IκBβ promoter has a κB
c© 2006 Biochemical Society
In vivo binding of NF-κB to the IκBβ promoter 123
Figure 7 TFIIH is not recruited to the IκBβ promoter in response to IL-1 stimulation of 1321N1 cells
1321N1 astrocytoma were stimulated in the presence or absence of IL-1β (10 ng/ml) for 1 h. Nuclear lysates were generated and immunoprecipitated with anti-p89 or control IgG antibodies.
Immunoprecipitated DNA was analysed for IL-8 and IκBβ promoter sequences by PCR and gel electrophoresis (A) and by quantitative real-time PCR analysis (B). Data from real-time PCR are
expressed as fold differences between DNA enrichment in the anti-p89 ChIP sample relative to IgG ChIP sample and are displayed as means +− S.E.M. for three or four independent experiments.
***P < 0.001 versus unstimulated control (unpaired t test).
site in a similar position. We examined the human IκBβ κB site
at the level of NF-κB binding, and assessed the functional con-
sequences of NF-κB activation on IκBβ promoter activity. We
were especially interested in understanding the role of NF-κB in
the differential induction of IκBα and IκBβ by IL-1β in human
astrocytes, a situation that leads to sustained activation of NF-κB
and likely chronic neuroinflammation.
EMSA analysis demonstrated that NF-κB, activated in response
to IL-1β, could interact with the IκBβ-κB site in addition to
two functionally competent κB sites from the IκBα promoter.
The consistent electrophoretic mobility of the NF-κB–DNA
complexes detected with different probes indicated that a similar
form of NF-κB was mediating binding in each case. This
likelihood was strengthened through competition EMSAs, where
the NF-κB complex was found to bind to both the β-κB and α-
κB1 probes with equal affinity. Further support came from the
immunodetection of the same Rel subunits in NF-κB complexes
bound to both sites in vitro. p65 was found to be contained in
all IL-1β-induced NF-κB complexes, with the presence of c-Rel
also apparent, although to a lesser extent. Thus EMSA analysis
showed that a form of NF-κB with substantial transactivation
potential can bind to the IκBβ promoter κB site in vitro. ChIP
analysis was performed to investigate whether this interaction
had any relevance in living cells. p65 was chosen as the target
Rel subunit since it had been identified in the NF-κB complexes
as the predominant subunit to interact with both the β-κB and
α-κB1 probes in vitro. Furthermore, its presence at a promoter
could point towards an up-regulation of transcriptional activity.
Interestingly, like the IκBα promoter, p65 was detected at the
IκBβ promoter in an IL-1β-dependent manner.
Previous studies have suggested that NF-κB activation has, at
best, a modest effect on IκBβ expression. Nevertheless, given the
binding of p65 to the IκBβ promoter induced by IL-1β, we ex-
amined the effect of NF-κB activation on IκBβ promoter activity
in transient transfection assays, where it was shown to confer
only a low level of inducibility. The effect of NF-κB activation on
endogenous IκBβ gene expression was then assessed at the level
of both mRNA and protein, where no up-regulation was observed.
This indicated that the binding of p65 to the IκBβ promoter was
insufficient to cause transcriptional activation of the gene.
p65 contains two independent TADs in its C-terminal portion
[31]. Through these TADs, p65 can interact with co-activators and
components of the basal transcription apparatus [27,28]. p65 has
in fact been shown to interact directly with general transcription
factors, thereby increasing the rate at which transcription is
initiated at the relevant promoter [26]. ChIP studies with anti-
RNA Pol II allowed us to monitor the recruitment of the enzyme
to the IκBβ, IκBα and IL-8 promoters. In addition, by selecting a
second target sequence downstream of the promoter, within which
to probe for the presence of RNA Pol II, it was possible to ascertain
whether the gene was being actively transcribed after 1 h IL-1β.
IL-8 is known to be strongly induced by IL-1β, while not being
expressed in basal state. Indeed, a major recruitment of RNA Pol II
to the IL-8 promoter was recorded in response to IL-1β. As the
enzyme was also detected within the IL-8 gene sequence in an
IL-1β-dependent manner, this appeared to be followed by tran-
scriptional activity. While RNA Pol II was detected at the IκBα
promoter in unstimulated cells, further enzyme was recruited
in response to IL-1β and, as for IL-8, RNA Pol II-mediated
transcription resulted. RNA Pol II was also detected at the IκBβ
promoter in the basal state. While IL-1β appeared to cause some
further engagement, no RNA Pol II was detected downstream
within the IκBβ gene sequence, in the presence or absence of
IL-1β stimulation. It should be noted that the target sequences in
both the IκBα and IL-8 genes were within exons, while the IκBβ
gene target was within intronic DNA. It has been suggested that
RNA Pol II accumulates at exons during transcription, making
coding DNA a preferable target in Pol II ChIP [32,33]. However,
technical difficulties precluded the use of a sequence within the
sufficiently large exons 3 or 5 in the IκBβ gene. The target
sequence used was just 5′ of exon 2. As the average chromatin size
was 750 bp, it was expected that Pol II-immunoprecipitated DNA
would have been enriched for this sequence, were the enzyme
present in exon 2 during transcription.
p65 can therefore bind to the IκBβ promoter in response to
IL-1β, although this does not result in efficient recruitment of
RNA Pol II. In addition, the modest levels of recruited polymerase
appear to stall at the promoter. As promoter clearance requires the
phosphorylation of Ser5 of the RNA polymerase II CTD hepta-
peptide sequence by the Cdk7 subunit of TFIIH [30,34], we
finally investigated whether this general transcription factor was
recruited to the IκBβ promoter post-IL-1β stimulation. However,
unlike the κB-responsive IL-8 promoter, p65 binding to the
IκBβ promoter was not followed by loading of TFIIH. A mech-
anism may thus be proposed whereby p65 binding to the IκBβ
promoter causes a slight recruitment of RNA Pol II but fails to
facilitate TFIIH loading, with a resulting absence of transcrip-
tional initiation and gene expression.
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The failure of IκBβ-promoter-bound p65 to interact efficiently
with the basal transcription apparatus, either directly or indirectly
through co-activators, may occur for various reasons. NF-κB can
bind to a range of κB site sequences and it has been proposed that
the nucleotide sequence of a κB site dictates the conformation
of the bound NF-κB dimer. This allosteric role for DNA has a
precedent in the binding characteristics of the nuclear receptor
protein family [35]. The NF-κB conformation induced by the
κB site has functional consequences. An alteration of the site
sequence can impact transcriptional activation mediated by bound
NF-κB, most likely by modifying the ability of NF-κB to interact
with other trans-acting factors or with co-activators [20,36]. Thus
an induced conformation that does not favour recruitment of co-
activators or basal transcription factors is one possible explanation
for the failure of IκBβ promoter-bound p65 to activate transcrip-
tion. However, an identical decameric κB site supports trans-
activation in the MIP (macrophage inflammatory protein)-2 and
MCP (monocyte chemoattractant protein)-1 promoters [37,38].
Furthermore, in the case of the MCP-1 promoter, p65–p65 homo-
dimers and p65–c-Rel heterodimers, the Rel subunits found
to bind to the IκBβ promoter κB site in vitro, display the ability to
activate transcription through this site [37]. However, it should
be noted that the sequence flanking the κB site also influences
the conformation of NF-κB–DNA complexes, as the structure of
DNA is sequence-dependent [39–41]. As the flanking sequences
differ between MCP-1and IκBβ, this could lead to the same NF-
κB complex binding to identical decameric κB site sequences,
but assuming different conformations due to the divergence in κB
site DNA structure imposed by surrounding bases.
The characterization of many promoters in which NF-κB is
known to play an important role in transcriptional activation has
revealed the requirement for numerous other trans-acting factors
and co-activators, combining to form a gene-specific enhanceo-
some [42,43]. p65 binding to the IκBβ promoter may provide
just one part of the combinatorial complex necessary for gene
expression. Other signals may be provided in a stimulus- and cell-
type-specific manner. In addition, post-translational modifications
of p65 have been shown to regulate interactions with co-activators.
Such modifications are stimulus-dependent and may even occur
in a promoter-specific manner, highlighting the complexities of
gene regulation at the level of the promoter [44,45].
The failure of NF-κB activation to elicit a substantial increase in
IκBβ gene expression has previously been demonstrated [8,13].
Here, the model is advanced to show that NF-κB can in fact
bind to the IκBβ promoter, but that this does not trigger efficient
general transcription factor or RNA Pol II recruitment or promoter
firing. The present findings also provide a potential mechanistic
understanding of the basis for sustained activation of NF-κB
in some systems. We have previously shown that IL-1β causes
sustained activation of NF-κB in human astrocytes and this is
likely to play a key role in promoting chronic inflammation in
the brain [46]. Such sustained activation coincides with strong
induction of IκBα, but lack of resynthesis of IκBβ, suggesting
the latter to be a key regulator of NF-κB in this system. We now
define the molecular basis of the differential effects of IL-1β on
IκBα and IκBβ expression in human astrocytes, in that IL-1β
fails to stimulate efficient recruitment or processing of the basal
transcriptional machinery at the IκBβ promoter. The delineation
of mechanisms that increase such an efficiency may be of great
value in up-regulating IκBβ expression and controlling chronic
activation of NF-κB in the brain.
This work was supported by funding from the Health Research Board of Ireland and Science
Foundation Ireland.
REFERENCES
1 Kopp, E. B. and Ghosh, S. (1995) NF-κB and rel proteins in innate immunity.
Adv. Immunol. 58, 1–27
2 Thanos, D. and Maniatis, T. (1995) NF-κB: a lesson in family values. Cell 80,
529–532
3 Nolan, G. P., Ghosh, S., Liou, H. C., Tempst, P. and Baltimore, D. (1991) DNA binding and
IκB inhibition of the cloned p65 subunit of NF-κB, a rel-related polypeptide. Cell 64,
961–969
4 Baeuerle, P. A. and Baltimore, D. (1988) IκB: a specific inhibitor of the NF-κB
transcription factor. Science 242, 540–546
5 Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D. and Miyamoto, S. (1995)
Rel/NF-κB/IκB family: intimate tales of association and dissociation. Genes Dev. 9,
2723–2735
6 Brockman, J. A., Scherer, D. C., McKinsey, T. A., Hall, S. M., Qi, X., Lee, W. Y. and Ballard,
D. W. (1995) Coupling of a signal response domain in IκBα to multiple pathways for
NF-κB activation. Mol. Cell. Biol. 15, 2809–2818
7 DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E. and Karin, M. (1997)
A cytokine-responsive IκB kinase that activates the transcription factor NF-κB.
Nature 388, 548–554
8 Thompson, J. E., Phillips, R. J., Erdjument-Bromage, H., Tempst, P. and Ghosh, S. (1995)
IκB-β regulates the persistent response in a biphasic activation of NF-κB. Cell 80,
573–582
9 Sun, S. C., Ganchi, P. A., Ballard, D. W. and Greene, W. C. (1993) NF-κB controls
expression of inhibitor IκBα: evidence for an inducible autoregulatory pathway.
Science 259, 1912–1915
10 Arenzana-Seisdedos, F., Turpin, P., Rodriguez, M., Thomas, D., Hay, R. T., Virelizier, J. L.
and Dargemont, C. (1997) Nuclear localization of IκBα promotes active transport of
NF-κB from the nucleus to the cytoplasm. J. Cell Sci. 110, 369–378
11 Beg, A. A., Sha, W. C., Bronson, R. T. and Baltimore, D. (1995) Constitutive NF-κB
activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice.
Genes Dev. 9, 2736–2746
12 Cheng, J. D., Ryseck, R. P., Attar, R. M., Dambach, D. and Bravo, R. (1998) Functional
redundancy of the nuclear factor κB inhibitors IκBα and IκBβ . J. Exp. Med. 188,
1055–1062
13 Bourke, E., Kennedy, E. J. and Moynagh, P. N. (2000) Loss of IκB-β is associated with
prolonged NF-κB activity in human glial cells. J. Biol. Chem. 275, 39996–40002
14 Budde, L. M., Wu, C., Tilman, C., Douglas, I. and Ghosh, S. (2002) Regulation of IκBβ
expression in testis. Mol. Biol. Cell 13, 4179–4194
15 Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory
Manual, 2nd edn, Cold Spring Harbor Laboratory Press, Cold Spring Harbor
16 Curran, N. M., Griffin, B. D., O’Toole, D., Brady, K. J., Fitzgerald, S. N. and Moynagh, P. N.
(2005) The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling
pathway in human astrocytes in a cannabinoid receptor-independent manner.
J. Biol. Chem. 280, 35797–35806
17 Saccani, S., Pantano, S. and Natoli, G. (2002) p38-dependent marking of inflammatory
genes for increased NF-κB recruitment. Nat. Immunol. 3, 69–75
18 Chakrabarti, S. K., James, J. C. and Mirmira, R. G. (2002) Quantitative assessment of
gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1: importance
of chromatin structure in directing promoter binding. J. Biol. Chem. 277, 13286–13293
19 Budde, L. M. and Ghosh, S. (2000) Cloning and characterization of the gene encoding
mouse IκBβ . Gene 247, 279–286
20 Leung, T. H., Hoffmann, A. and Baltimore, D. (2004) One nucleotide in a κB site can
determine cofactor specificity for NF-κB dimers. Cell 118, 453–464
21 Kunsch, C., Ruben, S. M. and Rosen, C. A. (1992) Selection of optimal κB/Rel
DNA-binding motifs: interaction of both subunits of NF-κB with DNA is required for
transcriptional activation. Mol. Cell. Biol. 12, 4412–4421
22 Le Bail, O., Schmidt-Ullrich, R. and Israel, A. (1993) Promoter analysis of the gene
encoding the IκB-α/MAD3 inhibitor of NF-κB: positive regulation by members of the
rel/NF-κB family. EMBO J. 12, 5043–5049
23 Moore, P. A., Ruben, S. M. and Rosen, C. A. (1993) Conservation of transcriptional
activation functions of the NF-κB p50 and p65 subunits in mammalian cells and
Saccharomyces cerevisiae. Mol. Cell. Biol. 13, 1666–1674
24 Bull, P., Morley, K. L., Hoekstra, M. F., Hunter, T. and Verma, I. M. (1990) The mouse
c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional
transactivation domain. Mol. Cell. Biol. 10, 5473–5485
25 Okamoto, T., Ono, T., Hori, M., Yang, J. P., Tetsuka, T., Kawabe, T. and Sonta, S. (1998)
Assignment of the IκB-β gene NFKBIB to human chromosome band 19q13.1 by in situ
hybridization. Cytogenet. Cell Genet. 82, 105–106
26 Schmitz, M. L., Stelzer, G., Altmann, H., Meisterernst, M. and Baeuerle, P. A. (1995)
Interaction of the COOH-terminal transactivation domain of p65 NF-κB with TATA-binding
protein, transcription factor IIB, and coactivators. J. Biol. Chem. 270, 7219–7226
c© 2006 Biochemical Society
In vivo binding of NF-κB to the IκBβ promoter 125
27 Gerritsen, M. E., Williams, A. J., Neish, A. S., Moore, S., Shi, Y. and Collins, T. (1997)
CREB-binding protein/p300 are transcriptional coactivators of p65. Proc. Natl.
Acad. Sci. U.S.A. 94, 2927–2932
28 Kee, B. L., Arias, J. and Montminy, M. R. (1996) Adaptor-mediated recruitment
of RNA polymerase II to a signal-dependent activator. J. Biol. Chem. 271,
2373–2375
29 Zawel, L. and Reinberg, D. (1995) Common themes in assembly and function of
eukaryotic transcription complexes. Annu. Rev. Biochem. 64, 533–561
30 Cismowski, M. J., Laff, G. M., Solomon, M. J. and Reed, S. I. (1995) KIN28 encodes a
C-terminal domain kinase that controls mRNA transcription in Saccharomyces cerevisiae
but lacks cyclin-dependent kinase-activating kinase (CAK) activity. Mol. Cell. Biol. 15,
2983–2992
31 Schmitz, M. L., dos Santos Silva, M. A. and Baeuerle, P. A. (1995) Transactivation domain
2 (TA2) of p65 NF-κB: similarity to TA1 and phorbol ester-stimulated activity and
phosphorylation in intact cells. J. Biol. Chem. 270, 15576–15584
32 Sandoval, J., Rodriguez, J. L., Tur, G., Serviddio, G., Pereda, J., Boukaba, A., Sastre, J.,
Torres, L., Franco, L. and Lopez-Rodas, G. (2004) RNAPol-ChIP: a novel application of
chromatin immunoprecipitation to the analysis of real-time gene transcription.
Nucleic Acids Res. 32, e88
33 Brodsky, A. S., Meyer, C. A., Swinburne, I. A., Hall, G., Keenan, B. J., Liu, X. S., Fox, E. A.
and Silver, P. A. (2005) Genomic mapping of RNA polymerase II reveals sites of
co-transcriptional regulation in human cells. Genome Biol. 6, R64
34 Trigon, S., Serizawa, H., Conaway, J. W., Conaway, R. C., Jackson, S. P. and Morange, M.
(1998) Characterization of the residues phosphorylated in vitro by different C-terminal
domain kinases. J. Biol. Chem. 273, 6769–6775
35 Rastinejad, F. (2001) Retinoid X receptor and its partners in the nuclear receptor family.
Curr. Opin. Struct. Biol. 11, 33–38
36 Chen-Park, F. E., Huang, D. B., Noro, B., Thanos, D. and Ghosh, G. (2002) The κB DNA
sequence from the HIV long terminal repeat functions as an allosteric regulator of HIV
transcription. J. Biol. Chem. 277, 24701–24708
37 Ueda, A., Ishigatsubo, Y., Okubo, T. and Yoshimura, T. (1997) Transcriptional regulation of
the human monocyte chemoattractant protein-1 gene: cooperation of two NF-κB sites and
NF-κB/Rel subunit specificity. J. Biol. Chem. 272, 31092–31099
38 Widmer, U., Manogue, K. R., Cerami, A. and Sherry, B. (1993) Genomic cloning and
promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1α, and MIP-1β ,
members of the chemokine superfamily of proinflammatory cytokines. J. Immunol. 150,
4996–5012
39 Tisne, C., Delepierre, M. and Hartmann, B. (1999) How NF-κB can be attracted by its
cognate DNA. J. Mol. Biol. 293, 139–150
40 Tisne, C., Hantz, E., Hartmann, B. and Delepierre, M. (1998) Solution structure of a
non-palindromic 16 base-pair DNA related to the HIV-1 κB site: evidence for BI–BII
equilibrium inducing a global dynamic curvature of the duplex. J. Mol. Biol. 279,
127–142
41 Tisne, C., Hartmann, B. and Delepierre, M. (1999) NF-κB binding mechanism: a nuclear
magnetic resonance and modeling study of a GGG → CTC mutation. Biochemistry 38,
3883–3894
42 Hoffmann (2002) Multiple control of interleukin-8 gene expression. J. Leukocyte Biol. 72,
847–855
43 Maniatis, T., Falvo, J. V., Kim, T. H., Kim, T. K., Lin, C. H., Parekh, B. S. and Wathelet,
M. G. (1998) Structure and function of the interferon-β enhanceosome. Cold Spring
Harbor Symp. Quant. Biol. 63, 609–620
44 Steinbrecher, K. A., Wilson, III, W., Cogswell, P. C. and Baldwin, A. S. (2005) Glycogen
synthase kinase 3β functions to specify gene-specific, NF-κB-dependent transcription.
Mol. Cell. Biol. 25, 8444–8455
45 Zhong, H., May, M. J., Jimi, E. and Ghosh, S. (2002) The phosphorylation status of
nuclear NF-κB determines its association with CBP/p300 or HDAC-1. Mol. Cell 9,
625–636
46 Griffin, B. D. and Moynagh, P. N. (2006) Persistent interleukin-1β signaling causes long
term activation of NF-κB in a promoter-specific manner in human glial cells.
J. Biol. Chem. 281, 10316–10326
Received 30 May 2006/21 June 2006; accepted 23 June 2006
Published as BJ Immediate Publication 23 June 2006, doi:10.1042/BJ20060786
c© 2006 Biochemical Society
